Results 211 to 220 of about 41,356 (289)

Skin Fragility and Hyperpigmentation in a Patient With HIV

open access: yesJEADV Clinical Practice
Catalina Retamal   +2 more
doaj   +1 more source

Peristomal bullous pemphigoid: expanding the spectrum of localized presentations. [PDF]

open access: yesAn Bras Dermatol
Ramírez-Bravo F   +5 more
europepmc   +1 more source

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes   +6 more
wiley   +1 more source

Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this randomized controlled trial, cumulative isotretinoin doses of 120 and 150 mg/kg showed similar relapse rates at 12 months. Both regimens achieved substantial and comparable reductions in inflammatory acne lesions across the face, chest and back.
Ruggero Cascio Ingurgio   +16 more
wiley   +1 more source

Ankyloblepharon‐ectodermal defects‐cleft lip/palate syndrome: a case report highlighting the importance of clinical diagnosis in a rare hereditary disorder

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Aikaterini Kyriakou   +7 more
wiley   +1 more source

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Updated S2k hidradenitis suppurativa (HS) guidelines provide expert consensus on diagnosis, assessment and comorbidities. Expanded substantially since the 2015 version, they reflect rapid growth in HS literature and aim to improve generalist‐level patient care through evidence‐informed, consensus‐based guidance.
G. B. E. Jemec   +36 more
wiley   +1 more source

Regression Equation for Predicting Source Strength Detection Rate in Iodine-125 Seed Brachytherapy. [PDF]

open access: yesCureus
Takanashi M   +6 more
europepmc   +1 more source

Immune‐related adverse events with mogamulizumab in cutaneous T‐cell lymphoma: A multicentre study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In a nationwide multicentre study of 403 patients with cutaneous T‐cell lymphoma treated with mogamulizumab, non‐MAR immune‐related adverse events were reported in 8.4% of patients across responding centres. These events were diverse, sometimes severe or persistent, and could occur late during mogamulizumab treatment.
David Neubauer   +28 more
wiley   +1 more source

Recurrent Bullous Pemphigoid: A Case Report. [PDF]

open access: yesCureus
Gowda Venkatesha RR   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy